{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:15:48Z","timestamp":1794024948867,"version":"4.8.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Antibody-drug conjugates (ADCs) are a therapeutic approach that embodies the \u201cmagic bullet\u201d concept envisioned by Paul Ehrlich. Since their initial clinical potential was recognized in the early 1980s, ADCs have undergone several generations of development to enhance their therapeutic index (Poon KA, et. al. 273(2):298-313, 2013). Recent advancements, particularly in the last third and the beginning of the fourth generation, have primarily focused on discovering new drug modalities and more potent cancer treatments, while also developing new linkers and improving site-specific and conjugation chemistries. The effectiveness and toxicity of ADCs are largely influenced by their overall physicochemical properties, especially hydrophobicity, plasma stability, resistance to payload release, and the efficient release of the payload at the target site (Saber H, et. al. 71(3):444-52, 2015), (Saber H, et. al. 107:104429, 2019). These properties are heavily dictated by the site of conjugation, conjugation chemistry, linkers, and payloads. Most payloads are hydrophobic and cannot undergo significant structural or functional changes without compromising their cytotoxicity. In contrast, linkers can be extensively modified to enhance the physicochemical characteristics of ADCs, improve stability, increase drug-to-antibody ratio (DAR), and reduce aggregation. This review will focus on the latest advancements in potent payloads with novel mechanisms of action, including immune-stimulating agents, protein degraders, radionuclides, light-activated photosensitizers for photoimmunotherapy, and dual-payload ADCs. Additionally, we will explore emerging linkers that offer varying stimuli for trigger payload release and improved release control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1208\/s12249-026-03445-z","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:37:53Z","timestamp":1781631473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Payload and Linker Designs for ADCs"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1998-5821","authenticated-orcid":false,"given":"Samson","family":"Gebretnsae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"10","key":"3445_CR1","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li H, Gou L, Li W, Wang Y. Antibody-drug conjugates: recent advances in payloads. Acta Pharm Sin B. 2023;13(10):4025\u201359. https:\/\/doi.org\/10.1016\/j.apsb.2023.06.015.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"3445_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3445_CR3","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas A, Teicher BA, Hassan R. Antibody\u2013drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(16)30030-4.","journal-title":"Lancet Oncol"},{"issue":"23","key":"3445_CR4","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.1021\/bc9002019","volume":"22","author":"L Ducry","year":"2010","unstructured":"Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioorg Med Chem Lett. 2010;22(23):6757\u201360. https:\/\/doi.org\/10.1021\/bc9002019.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"3445_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02489-2","volume":"24","author":"B Chen","year":"2025","unstructured":"Chen B, Zheng X, Wu J, Chen G, Yu J, Xu Y, et al. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer. 2025;24(1):279. https:\/\/doi.org\/10.1186\/s12943-025-02489-2.","journal-title":"Mol Cancer"},{"issue":"11","key":"3445_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/14712598.2023.2276873","volume":"23","author":"T Fujii","year":"2023","unstructured":"Fujii T, Matsuda Y. Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry. Expert Opin Biol Ther. 2023;23(11):1053\u201365. https:\/\/doi.org\/10.1080\/14712598.2023.2276873.","journal-title":"Expert Opin Biol Ther"},{"key":"3445_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.013","volume":"181","author":"PA Trail","year":"2018","unstructured":"Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018;181:126\u201342. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.07.013.","journal-title":"Pharmacol Ther"},{"issue":"19","key":"3445_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1209124.","journal-title":"N Engl J Med"},{"issue":"18","key":"3445_CR9","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30(18):2183\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.38.0410.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3445_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J Clin Oncol. 2020;38(2):155\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00172.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3445_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cac2.12577","volume":"44","author":"J Wang","year":"2024","unstructured":"Wang J, Liu Y, Zhang Q, Li W, Feng J, Wang X, et al. Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study. Cancer Commun. 2024;44(7):833\u201351. https:\/\/doi.org\/10.1002\/cac2.12577.","journal-title":"Cancer Commun"},{"issue":"15","key":"3445_CR12","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1002\/anie.201307628","volume":"53","author":"RV Chari","year":"2014","unstructured":"Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014;53(15):3796\u2013827. https:\/\/doi.org\/10.1002\/anie.201307628.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"3445_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101338","volume":"17","author":"B Valsasina","year":"2024","unstructured":"Valsasina B, Orsini P, Terenghi C, Ocana A. Present scenario and future landscape of payloads for ADCs: focus on DNA-interacting agents. Pharmaceuticals. 2024;17(10):1338. https:\/\/doi.org\/10.3390\/ph17101338.","journal-title":"Pharmaceuticals"},{"issue":"8","key":"3445_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081707","volume":"14","author":"S Han","year":"2022","unstructured":"Han S, Lim KS, Blackburn BJ, Yun J, Putnam CW, Bull DA, et al. The potential of topoisomerase inhibitor-based antibody-drug conjugates. Pharmaceutics. 2022;14(8):1707. https:\/\/doi.org\/10.3390\/pharmaceutics14081707.","journal-title":"Pharmaceutics"},{"issue":"6","key":"3445_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1078-0432.CCR-22-3640","volume":"29","author":"Y Pommier","year":"2023","unstructured":"Pommier Y, Thomas A. New life of topoisomerase I inhibitors as antibody-drug conjugate warheads. Clin Cancer Res. 2023;29(6):991\u20133. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3640.","journal-title":"Clin Cancer Res"},{"key":"3445_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104355","volume":"198","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Pandiella A, Vargas-Castrill E, D\u00edaz-Rodr\u00edguez E, Iglesias-Hernang\u00f3mez T, Mart\u00ednez Cano C. Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol. 2024;198:104355. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104355.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3445_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241309461","volume":"17","author":"D Izzo","year":"2025","unstructured":"Izzo D, Ascione L, Guidi L, Marsicano RM, Koukoutzeli C, Trapani D, et al. Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Ther Adv Med Oncol. 2025;17:17588359241309461. https:\/\/doi.org\/10.1177\/17588359241309461.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3445_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023;16(1):3. https:\/\/doi.org\/10.1186\/s13045-022-01397-y.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3445_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2021","unstructured":"Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2(1):18\u201333. https:\/\/doi.org\/10.1038\/s43018-020-00136-x.","journal-title":"Nat Cancer"},{"issue":"1","key":"3445_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00364-1","volume":"7","author":"C Rolfo","year":"2023","unstructured":"Rolfo C, Giovannetti E, Martinez P, McCue S, Naing A. Applications and clinical trial landscape using toll-like receptor agonists to reduce the toll of cancer. npj Precis Oncol. 2023;7(1):26. https:\/\/doi.org\/10.1038\/s41698-023-00364-1.","journal-title":"npj Precis Oncol"},{"issue":"8","key":"3445_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012500","volume":"13","author":"C Fu","year":"2025","unstructured":"Fu C. Where does ISAC (immune-stimulating antibody conjugates) go from here? J Immunother Cancer. 2025;13(8):e012500. https:\/\/doi.org\/10.1136\/jitc-2025-012500.","journal-title":"J Immunother Cancer"},{"key":"3445_CR22","doi-asserted-by":"publisher","first-page":"24968","DOI":"10.1021\/acs.jmedchem.5c01908","volume":"68","author":"S Fang","year":"2025","unstructured":"Fang S, Benjamin SR, Wu L, Rahman MA, Elder KK, Ojo VT, et al. Dissecting the efficacy and immunogenicity of TLR7 agonist\u2013antibody conjugates through the lens of Fc effector function, conjugation strategies, and linker cleavability. J Med Chem. 2025;68:24968\u201385. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01908.","journal-title":"J Med Chem"},{"issue":"7","key":"3445_CR23","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","volume":"15","author":"JW Buecheler","year":"2018","unstructured":"Buecheler JW, Winzer M, Tonillo J, Weber C, Gieseler H. Impact of payload hydrophobicity on the stability of antibody-drug conjugates. Mol Pharm. 2018;15(7):2656\u201364. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00177.","journal-title":"Mol Pharm"},{"issue":"2","key":"3445_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1021\/acs.bioconjchem.3c00535","volume":"35","author":"A Zhang","year":"2024","unstructured":"Zhang A, Seiss K, Laborde L, Palacio-Ramirez S, Guthy D, Lanter M, et al. Design, synthesis, and in vitro and in vivo evaluation of Cereblon binding Bruton\u2019s Tyrosine Kinase (BTK) degrader CD79b targeted antibody-drug conjugates. Bioconjug Chem. 2024;35(2):140\u20136. https:\/\/doi.org\/10.1021\/acs.bioconjchem.3c00535.","journal-title":"Bioconjug Chem"},{"issue":"12","key":"3445_CR25","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1158\/1535-7163.MCT-18-0643","volume":"17","author":"CS Neumann","year":"2018","unstructured":"Neumann CS, Olivas KC, Anderson ME, Cochran JH, Jin S, Li F. Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates. Mol Cancer Ther. 2018;17(12):2633\u201342. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0643.","journal-title":"Mol Cancer Ther"},{"key":"3445_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118019","volume":"298","author":"M Xi","year":"2025","unstructured":"Xi M, Zhang F, Zhu J, Shen H, Wu C, Gao X. Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy. Eur J Med Chem. 2025;298:118019. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118019.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"3445_CR27","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1021\/acs.bioconjchem.3c00366","volume":"34","author":"K Chan","year":"2023","unstructured":"Chan K, Sathyamurthi PS, Queisser MA, Mullin M, Shrives H, Coe DM, et al. Antibody-proteolysis targeting chimera conjugate enables selective degradation of Receptor-Interacting Serine\/Threonine-Protein Kinase 2 in HER2+ cell lines. Bioconjug Chem. 2023;34(11):2049\u201354. https:\/\/doi.org\/10.1021\/acs.bioconjchem.3c00366.","journal-title":"Bioconjug Chem"},{"key":"3445_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116837","volume":"279","author":"N Pravin","year":"2024","unstructured":"Pravin N, J\u00f3\u017awiak K. PROTAC unleashed: unveiling the synthetic approaches and potential therapeutic applications. Eur J Med Chem. 2024;279:116837. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116837.","journal-title":"Eur J Med Chem"},{"issue":"22","key":"3445_CR29","doi-asserted-by":"publisher","first-page":"23676","DOI":"10.1021\/acs.jmedchem.5c01911","volume":"68","author":"L Gioiello","year":"2025","unstructured":"Gioiello L, Di Martino RMC, Pirali T. Expanding the scope of PROTACs: opportunities and challenges in topical delivery. J Med Chem. 2025;68(22):23676\u201389. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01911.","journal-title":"J Med Chem"},{"issue":"6","key":"3445_CR30","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1021\/acs.bioconjchem.2c00178","volume":"33","author":"N B\u00f6hnke","year":"2022","unstructured":"B\u00f6hnke N, Berger M, Griebenow N, Rottmann A, Erkelenz M, Hammer S, et al. A novel NAMPT inhibitor-based antibody-drug conjugate payload class for cancer therapy. Bioconjug Chem. 2022;33(6):1210\u201321. https:\/\/doi.org\/10.1021\/acs.bioconjchem.2c00178.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"3445_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","volume":"20","author":"V Figueroa-Vazquez","year":"2021","unstructured":"Figueroa-Vazquez V, Ko J, Breunig C, Baumann A, Giesen N, P\u00e1lfi A. HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2021;20(2):367\u201378. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0287.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"3445_CR32","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1124\/dmd.119.086595","volume":"47","author":"Y Ma","year":"2019","unstructured":"Ma Y, Dela Cruz-Chuh J, Khojasteh SC, Dragovich PS, Pillow TH, Zhang D. Carfilzomib is not an appropriate payload of antibody-drug conjugates due to rapid inactivation by lysosomal enzymes. Drug Metab Dispos. 2019;47(8):884\u20139. https:\/\/doi.org\/10.1124\/dmd.119.086595.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3445_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","volume":"4","author":"ZN Lei","year":"2023","unstructured":"Lei ZN, Tian Q, Teng QX, Wurpel JND, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023;4(3):e265. https:\/\/doi.org\/10.1002\/mco2.265.","journal-title":"MedComm"},{"issue":"1","key":"3445_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2498162","volume":"17","author":"M Wen","year":"2025","unstructured":"Wen M, Yu A, Park Y, Calarese D, Gerber HP, Yin G. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations. MAbs. 2025;17(1):2498162. https:\/\/doi.org\/10.1080\/19420862.2025.2498162.","journal-title":"MAbs"},{"issue":"3","key":"3445_CR35","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/anie.201608292","volume":"56","author":"MR Levengood","year":"2017","unstructured":"Levengood MR, Zhang X, Hunter JH, Emmerton KK, Miyamoto JB, Lewis TS, et al. Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates. Angew Chem Int Ed Engl. 2017;56(3):733\u20137. https:\/\/doi.org\/10.1002\/anie.201608292.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"6","key":"3445_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","volume":"15","author":"SM Larson","year":"2015","unstructured":"Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15(6):347\u201360. https:\/\/doi.org\/10.1038\/nrc3925.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3445_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/imt.10.114","volume":"3","author":"RM Sharkey","year":"2011","unstructured":"Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy Lond. 2011;3(3):349\u201370. https:\/\/doi.org\/10.2217\/imt.10.114.","journal-title":"Immunotherapy Lond"},{"issue":"1","key":"3445_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-019-0524-9","volume":"17","author":"OO Peltek","year":"2019","unstructured":"Peltek OO, Muslimov AR, Zyuzin MV, Timin AS. Current outlook on radionuclide delivery systems: from design consideration to translation into clinics. J Nanobiotechnol. 2019;17(1):90. https:\/\/doi.org\/10.1186\/s12951-019-0524-9.","journal-title":"J Nanobiotechnol"},{"issue":"8","key":"3445_CR39","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","volume":"52","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi H, Choyke LP. Near-infrared photoimmunotherapy of cancer. Acc Chem Res. 2019;52(8):2332\u20139. https:\/\/doi.org\/10.1021\/acs.accounts.9b00273.","journal-title":"Acc Chem Res"},{"issue":"9","key":"3445_CR40","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1021\/acs.molpharmaceut.8b00002","volume":"15","author":"Y Maruoka","year":"2018","unstructured":"Maruoka Y, Nagaya T, Sato K, Ogata F, Okuyama S, Choyke PL, et al. Near infrared photoimmunotherapy with combined exposure of external and interstitial light sources. Mol Pharm. 2018;15(9):3634\u201341. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00002.","journal-title":"Mol Pharm"},{"issue":"12","key":"3445_CR41","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/nm.2554","volume":"17","author":"M Mitsunaga","year":"2011","unstructured":"Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17(12):1685\u201391. https:\/\/doi.org\/10.1038\/nm.2554.","journal-title":"Nat Med"},{"issue":"12","key":"3445_CR42","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/jnci\/90.12.889","volume":"90","author":"TJ Dougherty","year":"1998","unstructured":"Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889\u2013905. https:\/\/doi.org\/10.1093\/jnci\/90.12.889.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3445_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01159-2","volume":"9","author":"Y Lu","year":"2025","unstructured":"Lu Y, Huang W, Li Y, Xu Y, Wei Q, Sha C, et al. Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology. npj Precis Oncol. 2025;9(1):374. https:\/\/doi.org\/10.1038\/s41698-025-01159-2.","journal-title":"npj Precis Oncol"},{"issue":"4","key":"3445_CR44","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150089","volume":"35","author":"C Peters","year":"2015","unstructured":"Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):e00225. https:\/\/doi.org\/10.1042\/BSR20150089.","journal-title":"Biosci Rep"},{"issue":"4","key":"3445_CR45","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","volume":"14","author":"SC Alley","year":"2010","unstructured":"Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4):529\u201337. https:\/\/doi.org\/10.1016\/j.cbpa.2010.06.170.","journal-title":"Curr Opin Chem Biol"},{"key":"3445_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1669592","volume":"13","author":"D Wu","year":"2025","unstructured":"Wu D, Yang K, He R, Yin R, Shui L. Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs. Front Cell Dev Biol. 2025;13:1669592. https:\/\/doi.org\/10.3389\/fcell.2025.1669592.","journal-title":"Front Cell Dev Biol"},{"key":"3445_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114612","volume":"391","author":"Q Fu","year":"2026","unstructured":"Fu Q, Kong X, Liu Y, Liu M, Huang K, Wang PG, et al. The role of hydrophilic linkers in next-generation antibody-drug conjugates. J Control Release. 2026;391:114612. https:\/\/doi.org\/10.1016\/j.jconrel.2026.114612.","journal-title":"J Control Release"},{"issue":"7","key":"3445_CR48","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33(7):733\u20135. https:\/\/doi.org\/10.1038\/nbt.3212.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3445_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, et al. Antibody-drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18(1):51. https:\/\/doi.org\/10.1186\/s13045-025-01704-3.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"3445_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113080","volume":"11","author":"S Balamkundu","year":"2023","unstructured":"Balamkundu S, Liu CF. Lysosomal-cleavable peptide linkers in antibody-drug conjugates. Biomedicines. 2023;11(11):3080. https:\/\/doi.org\/10.3390\/biomedicines11113080.","journal-title":"Biomedicines"},{"key":"3445_CR51","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nrc1949","volume":"6","author":"MM Mohamed","year":"2006","unstructured":"Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6:764\u201375. https:\/\/doi.org\/10.1038\/nrc1949.","journal-title":"Nat Rev Cancer"},{"key":"3445_CR52","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1016\/s0960-894x(98)00609-x","volume":"8","author":"GM Dubowchik","year":"1998","unstructured":"Dubowchik GM, Firestone RA. Cathepsin B-sensitive dipeptide prodrugs. Bioorg Med Chem Lett. 1998;8:3341\u20136. https:\/\/doi.org\/10.1016\/s0960-894x(98)00609-x.","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"3445_CR53","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/1535-7163.MCT-22-0362","volume":"21","author":"SYY Ha","year":"2022","unstructured":"Ha SYY, Anami Y, Yamazaki CM, Xiong W, Haase CM, Olson SD, et al. An enzymatically cleavable tripeptide linker for maximizing the therapeutic index of antibody-drug conjugates. Mol Cancer Ther. 2022;21(9):1449\u201361. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0362.","journal-title":"Mol Cancer Ther"},{"key":"3445_CR54","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody\u2013drug conjugates. Chem Soc Rev. 2019;48:4361\u201374.","journal-title":"Chem Soc Rev"},{"key":"3445_CR55","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor. Clin Cancer Res. 2016;22:5097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822.","journal-title":"Clin Cancer Res"},{"key":"3445_CR56","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"key":"3445_CR57","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ejmech.2017.08.008","volume":"142","author":"S Kolodych","year":"2017","unstructured":"Kolodych S, Michel C, Delacroix S, Koniev O, Ehkirch A, Eberova J, et al. Development and evaluation of \u03b2-galactosidase-sensitive antibody\u2013drug conjugates. Eur J Med Chem. 2017;142:376\u201382. https:\/\/doi.org\/10.1016\/j.ejmech.2017.08.008.","journal-title":"Eur J Med Chem"},{"key":"3445_CR58","first-page":"1195","volume":"58","author":"K Bosslet","year":"1998","unstructured":"Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998;58:1195\u2013201 (PMID: 9515805).","journal-title":"Cancer Res"},{"issue":"15","key":"3445_CR59","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2174\/1381612023394485","volume":"8","author":"M de Graaf","year":"2002","unstructured":"de Graaf M, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. Beta-glucuronidase-mediated drug release. Curr Pharm Des. 2002;8(15):1391\u2013403. https:\/\/doi.org\/10.2174\/1381612023394485.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"3445_CR60","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2174\/0929867013372634","volume":"8","author":"FM de Groot","year":"2001","unstructured":"de Groot FM, Damen EW, Scheeren HW. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem. 2001;8(9):1093\u2013122. https:\/\/doi.org\/10.2174\/0929867013372634.","journal-title":"Curr Med Chem"},{"issue":"6","key":"3445_CR61","first-page":"1194","volume":"56","author":"LE Gerweck","year":"1996","unstructured":"Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 1996;56(6):1194\u20138.","journal-title":"Cancer Res"},{"issue":"4","key":"3445_CR62","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/jmri.10181","volume":"16","author":"RJ Gillies","year":"2002","unstructured":"Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging. 2002;16(4):430\u201350. https:\/\/doi.org\/10.1002\/jmri.10181.","journal-title":"J Magn Reson Imaging"},{"issue":"5","key":"3445_CR63","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrm.2017.132","volume":"19","author":"M Kaksonen","year":"2018","unstructured":"Kaksonen M, Roux A. Mechanisms of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2018;19(5):313\u201326. https:\/\/doi.org\/10.1038\/nrm.2017.132.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"14","key":"3445_CR64","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","volume":"24","author":"EY Jen","year":"2018","unstructured":"Jen EY, Ko CW, Lee JE, Del Valle PL, Aydanian A, Jewell C, et al. FDA approval: Gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018;24(14):3242\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3179.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3445_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/bc010021y","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47\u201358. https:\/\/doi.org\/10.1021\/bc010021y.","journal-title":"Bioconjug Chem"},{"key":"3445_CR66","doi-asserted-by":"crossref","unstructured":"Zaro, J. (2015). Mylotarg: Revisiting Its Clinical Potential Post-Withdrawal. In: Wang, J., Shen, WC., Zaro, J. (eds) Antibody-Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, vol 17. Springer, 2015. p 179 \u2013 190.","DOI":"10.1007\/978-3-319-13081-1_10"},{"issue":"16","key":"3445_CR67","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"issue":"22","key":"3445_CR68","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"Y Loriot","year":"2021","unstructured":"Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, Fl\u00e9chon A, Jain RK, Gupta S, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474\u201385. https:\/\/doi.org\/10.1200\/JCO.20.03489.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3445_CR69","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1021\/acs.bioconjchem.2c00314","volume":"33","author":"T Rady","year":"2022","unstructured":"Rady T, Turelli L, Nothisen M, Tobaldi E, Erb S, Thoreau F, et al. A novel family of acid-cleavable linker based on cyclic acetal motifs for the production of antibody-drug conjugates with high potency and selectivity. Bioconjug Chem. 2022;33(10):1860\u20136. https:\/\/doi.org\/10.1021\/acs.bioconjchem.2c00314.","journal-title":"Bioconjug Chem"},{"key":"3445_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2024.102552","volume":"84","author":"S Zhao","year":"2025","unstructured":"Zhao S, Yu N, Han H, Guo S, Murthy N. Advances in acid-degradable and enzyme-cleavable linkers for drug delivery. Curr Opin Chem Biol. 2025;84:102552. https:\/\/doi.org\/10.1016\/j.cbpa.2024.102552.","journal-title":"Curr Opin Chem Biol"},{"key":"3445_CR71","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/bc9002019","volume":"21","author":"L Ducry","year":"2010","unstructured":"Ducry L, Stump B. Antibody\u2013drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21:5\u201313. https:\/\/doi.org\/10.1021\/bc9002019.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"3445_CR72","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s0169-409x(02)00179-5","volume":"55","author":"G Saito","year":"2003","unstructured":"Saito G, Swanson JA, Lee KD. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev. 2003;55(2):199\u2013215. https:\/\/doi.org\/10.1016\/s0169-409x(02)00179-5.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3445_CR73","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/bc900315y","volume":"21","author":"HK Erickson","year":"2010","unstructured":"Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010;21(1):84\u201392. https:\/\/doi.org\/10.1021\/bc900315y.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"3445_CR74","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1039\/c6sc01831a","volume":"8","author":"TH Pillow","year":"2017","unstructured":"Pillow TH, Sadowsky JD, Zhang D, Yu SF, Del Rosario G, Xu K, et al. Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. Chem Sci. 2017;8(1):366\u201370. https:\/\/doi.org\/10.1039\/c6sc01831a.","journal-title":"Chem Sci"},{"issue":"Suppl 1","key":"3445_CR75","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10875-016-0265-6","volume":"36","author":"D Schumacher","year":"2016","unstructured":"Schumacher D, Hackenberger CP, Leonhardt H, Helma J. Current status: site-specific antibody drug conjugates. J Clin Immunol. 2016;36(Suppl 1):100\u20137. https:\/\/doi.org\/10.1007\/s10875-016-0265-6.","journal-title":"J Clin Immunol"},{"issue":"6","key":"3445_CR76","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrc1367","volume":"4","author":"JM Brown","year":"2004","unstructured":"Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437\u201347. https:\/\/doi.org\/10.1038\/nrc1367.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3445_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00833-8","volume":"7","author":"Y Wang","year":"2022","unstructured":"Wang Y, Xiao D, Li J, Fan S, Xie F, Zhong W, et al. From prodrug to pro-prodrug: hypoxia-sensitive antibody-drug conjugates. Signal Transduct Target Ther. 2022;7(1):20. https:\/\/doi.org\/10.1038\/s41392-021-00833-8.","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"3445_CR78","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1039\/d2cc06677g","volume":"59","author":"N Ashman","year":"2023","unstructured":"Ashman N, Bargh JD, Walsh SJ, Greenwood RD, Tiberghien A, Carroll JS, et al. Peroxide-cleavable linkers for antibody-drug conjugates. Chem Commun (Camb). 2023;59(13):1841\u20134. https:\/\/doi.org\/10.1039\/d2cc06677g.","journal-title":"Chem Commun (Camb)"},{"issue":"7","key":"3445_CR79","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","volume":"8","author":"D Trachootham","year":"2009","unstructured":"Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579\u201391. https:\/\/doi.org\/10.1038\/nrd2803.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3445_CR80","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/btm2.10014","volume":"1","author":"J Liang","year":"2016","unstructured":"Liang J, Liu B. ROS-responsive drug delivery systems. Bioeng Transl Med. 2016;1(3):239\u201351. https:\/\/doi.org\/10.1002\/btm2.10014.","journal-title":"Bioeng Transl Med"},{"issue":"2","key":"3445_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s41061-025-00497-w","volume":"383","author":"J Zhang","year":"2025","unstructured":"Zhang J, Yang Z, Liu Y, Liu Y, Qu J, Pan X. Recent advances in smart linkage strategies for developing drug conjugates for targeted delivery. Top Curr Chem (Cham). 2025;383(2):13. https:\/\/doi.org\/10.1007\/s41061-025-00497-w.","journal-title":"Top Curr Chem (Cham)"},{"issue":"4","key":"3445_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040670","volume":"13","author":"MA Rahim","year":"2021","unstructured":"Rahim MA, Jan N, Khan S, Shah H, Madni A, Khan A, et al. Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting. Cancers (Basel). 2021;13(4):670. https:\/\/doi.org\/10.3390\/cancers13040670.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3445_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ph15060655","volume":"15","author":"AN Johan","year":"2022","unstructured":"Johan AN, Li Y. Development of photoremovable linkers as a novel strategy to improve the pharmacokinetics of drug conjugates and their potential application in antibody-drug conjugates for cancer therapy. Pharmaceuticals (Basel). 2022;15(6):655. https:\/\/doi.org\/10.3390\/ph15060655.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"24","key":"3445_CR84","doi-asserted-by":"publisher","first-page":"20667","DOI":"10.1021\/jacs.5c03878","volume":"147","author":"H Xu","year":"2025","unstructured":"Xu H, Zheng M, Ye D, An J, Liu Z, Tang Z, et al. Ultrasound-triggered activation of p-Azidobenzyloxycarbonyl-based prodrugs via radical-mediated cascade elimination. J Am Chem Soc. 2025;147(24):20667\u201379. https:\/\/doi.org\/10.1021\/jacs.5c03878.","journal-title":"J Am Chem Soc"},{"issue":"6","key":"3445_CR85","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"3445_CR86","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736\u201342. https:\/\/doi.org\/10.1038\/bjc.2017.367.","journal-title":"Br J Cancer"},{"issue":"8","key":"3445_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082160","volume":"15","author":"A Kondrashov","year":"2023","unstructured":"Kondrashov A, Sapkota S, Sharma A, Riano I, Kurzrock R, Adashek JJ. Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload. Pharmaceutics. 2023;15(8):2160. https:\/\/doi.org\/10.3390\/pharmaceutics15082160.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3445_CR88","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.neo.2020.12.001","volume":"23","author":"E Khera","year":"2021","unstructured":"Khera E, Cilliers C, Smith MD, Ganno ML, Lai KC, Keating TA, et al. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping. Neoplasia. 2021;23(2):210\u201321. https:\/\/doi.org\/10.1016\/j.neo.2020.12.001.","journal-title":"Neoplasia"},{"issue":"2","key":"3445_CR89","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.2108","volume":"30","author":"BQ Shen","year":"2012","unstructured":"Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184\u20139. https:\/\/doi.org\/10.1038\/nbt.2108.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"3445_CR90","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1021\/bc200148v","volume":"22","author":"AD Baldwin","year":"2011","unstructured":"Baldwin AD, Kiick KL. Tunable degradation of maleimide-thiol adducts in reducing environments. Bioconjug Chem. 2011;22(10):1946\u201353. https:\/\/doi.org\/10.1021\/bc200148v.","journal-title":"Bioconjug Chem"},{"issue":"10","key":"3445_CR91","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1021\/bc500357n","volume":"25","author":"LN Tumey","year":"2014","unstructured":"Tumey LN, Charati M, He T, Sousa E, Ma D, Han X, et al. Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug Chem. 2014;25(10):1871\u201380. https:\/\/doi.org\/10.1021\/bc500357n.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"3445_CR92","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.7150\/thno.95469","volume":"14","author":"I Bibi","year":"2024","unstructured":"Bibi I, Mushtaq S, Lee KC, Park JA, Kim JY. From molecules to medicine: thiol selective bioconjugation in synthesis of diagnostic and therapeutic radiopharmaceuticals. Theranostics. 2024;14(6):2396\u2013426. https:\/\/doi.org\/10.7150\/thno.95469.","journal-title":"Theranostics"},{"key":"3445_CR93","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/d0cs00310g","volume":"50","author":"SJ Walsh","year":"2021","unstructured":"Walsh SJ, Bargh JD, Dannheim MF, Hanby AR, Seki H, Counsell AJ, et al. Site-selective modification strategies in antibody\u2013drug conjugates. Chem Soc Rev. 2021;50:1305\u201353. https:\/\/doi.org\/10.1039\/d0cs00310g.","journal-title":"Chem Soc Rev"},{"issue":"9","key":"3445_CR94","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1021\/bc500297p","volume":"25","author":"KL AntibodyAntibody","year":"2014","unstructured":"AntibodyAntibody KL, et al. (Mersana Therapeutics) Development of a novel antibody\u2013drug conjugate platform based on a flexible, biodegradable polymer scaffold. Bioconjug Chem. 2014;25(9):1609\u201322. https:\/\/doi.org\/10.1021\/bc500297p.","journal-title":"Bioconjug Chem"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03445-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03445-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03445-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:03:47Z","timestamp":1790280227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03445-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3445"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03445-z","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has no financial or non-financial conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"239"}}